Pancreatic Cancer Research

ResearcherHenry Ford HealthNo recent work listed

Munther Ajlouni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1544-2787; OpenAlex author ID A5113526567. Sources: ClinicalTrials.gov.

Their work

Papers
2 (first author 0, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 2

  1. Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer. Co-author DOI 10.1016/j.omto.2020.11.006↗
  2. Stereotactic Body Radiotherapy for Elderly Patients With Medically Inoperable Pancreatic Cancer. Last author DOI 10.1097/coc.0000000000000090↗

Trials 1

  1. Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma Principal investigator NCT00415454↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenneth N. Barton · 1 shared paper, 2021 · strength 0.12
  2. David Kwon · 1 shared paper, 2021 · strength 0.12
  3. Gazala Naaz Khan · 1 shared paper, 2021 · strength 0.12
  4. Raphael L. Yechieli · 1 shared paper, 2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.